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from interviews with practising Spanish GPs and psychiatrists.
Costs from ofﬁcial price/tariff lists were applied. Model out-
comes included total treatment cost, quality-adjusted life years
(QALYs) and symptom-free days (SFD). The robustness of ﬁnd-
ings was assessed in sensitivity analyses. RESULTS: In primary
care, incremental cost per QALY for duloxetine vs Venalaxine
XR was €29,457 and for duloxetine vs SSRIs was between
€11,867–€21,957 (extreme values vs paroxetine and ﬂuoxetine,
respectively). Incremental cost per SFD was 13€ vs. Venlafaxine
XR and ranged from 14€ to 26€ vs. paroxetine and ﬂuoxetine
respectively. In secondary care duloxetine was dominant vs. all
the drugs except for the comparison with ﬂuoxetine (cost per
QALY gained was 650€ and cost per additional SFD was 1€).
Results were sensitive to changes in the trial remission and
response rates, and in the distribution of switch therapy options.
CONCLUSION: Duloxetine showed a reasonable cost-
effectiveness ratio vs. the comparator drugs and could therefore
be considered a cost-effective treatment for MDD patients in
primary and secondary care in Spain.
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OBJECTIVES: To assess the cost-effectiveness of escitalopram
versus generic paroxetine in the treatment of generalized anxiety
disorder (GAD) in Norway. METHODS: Cost-effectiveness
analysis was based on a decision-tree model, reﬂecting the
current guidance for the treatment of GAD. Escitalopram
10–20 mg/day was compared to paroxetine 20–50 mg/day, the
only SSRIs licensed for the treatment of GAD in Norway. Initial
treatment started in primary care; failure to respond to a second-
line SSRI after switch from initial treatment resulted in referral to
a psychiatrist. The evaluation was performed over a 9-month
time horizon. Model data sources included published clinical
trials and standard national data sources. The main effectiveness
outcome was ﬁrst-line treatment success, deﬁned as a response
after 12 weeks of treatment (50% reduction in HAM-A) and
absence of relapse during the following 24 weeks. Other out-
comes included quality-adjusted life years (QALYs), rate of main-
tained treatment response (response at week 12 maintained at
week 36) and rate of referrals to secondary care. The analysis
was performed from the societal perspective and evaluated direct
treatment costs, including out-of-pocket payments and costs
covered by health insurance. RESULTS: Patients treated with
escitalopram had 11.3% higher ﬁrst-line success and 5.4%
higher maintained response rates compared with paroxetine-
treated patients. Rates of referrals to secondary care were 5.5%
lower with escitalopram compared with paroxetine. Per patient
direct treatment costs associated with escitalopram and paroxet-
ine treatment amounted to NOK 4424 and NOK 4172, respec-
tively. Incremental cost-effectiveness ratio (ICER) was NOK
2,230 per ﬁrst-line treatment response and NOK 37,612 per
QALY. Sensitivity analyses demonstrated robustness of the model
to changes in key input parameters. CONCLUSION: Escitalo-
pram appears to be cost-effective compared with paroxetine in
the treatment of GAD in Norway, based on direct treatment
costs.
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OBJECTIVES: The oral variant of the antipsychotic drug risperi-
done will lose patent protection at the end of 2007, which opens
the market for generic variants. However, since many schizo-
phrenic patients suffer from paranoia, some of them will be less
willing to take a different drug. Switching might therefore cause
non-compliance, which is in its turn the most important predic-
tor of relapse and hospitalisation in schizophrenia. We therefore
made an estimation of potential economic consequences regard-
ing drug and hospitalisation costs when stable patients in The
Netherlands currently using branded risperidone are switched to
the generic version. METHODS: A simple health economic
model was developed, based on published data regarding hospi-
talisation durations, rates of compliance, relapse, and additional
relapse resulting from switching to generics. A one-year perspec-
tive was applied. RESULTS: Due to a somewhat higher relapse
rate after switching to generics in the ﬁrst year after the switch,
total per-patient drug and hospitalisation costs were estimated to
be higher for the generic product as compared to the branded
product (€5110 and €4680, respectively). Sensitivity analyses
showed the stability of the relative result. CONCLUSION:
Switching patients who are stabilised on branded risperidone to
the generic version might cause higher health care costs. The
analysis is dependent on assumptions, but given their evidence-
based character, there is sufﬁcient reason to believe that the
relative result will hold in countries where only a little difference
will exist between the price of branded and generic risperidone
after the patent expiry.
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OBJECTIVES: Little is known about the direct costs of individu-
als with mild cognitive impairment (MCI). This study investi-
gates the direct costs associated with MCI according to recent
diagnostic criteria from a societal perspective. METHODS: A
total of 452 primary care patients aged 75+ from Leipzig,
Germany, were investigated in face-to-face interviews regarding
MCI according to the current diagnostic criteria of the Interna-
tional Working Group on MCI, resource utilisation and costs
(cost diary), as well as chronic medical illness (Chronic Disease
Score). Resource utilisation was monetarily valued using 2004/
2005 prices. RESULTS: Mean annual direct costs were EUR
4443 for patients with MCI (N = 39) and EUR 3,814 for patients
without MCI (N = 413) (p = 0.34). Looking at the cost compo-
nents, patients with and without MCI only signiﬁcantly differed
regarding pharmaceutical costs (EUR 1210 vs. EUR 1062;
p < 0.05) not caused by antidementive drugs. CONCLUSION:
Direct costs of individuals having MCI are not signiﬁcantly
increased in comparison to direct costs of individuals without
cognitive deﬁcits.
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